Research Article
Double-Negative T Cells Attenuate Cisplatin-Induced Acute Kidney Injury via Upregulating IL-10/AT2R Axis

Jing Gong, Jingjing Wu, Mingshun Zhang, and Weihua Gan

1Department of Pediatric Nephrology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China
2Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
3Department of Immunology, Nanjing Medical University, Nanjing, China

Correspondence should be addressed to Weihua Gan; weihuagan@njmu.edu.cn

Received 24 May 2022; Revised 11 July 2022; Accepted 15 July 2022; Published 30 July 2022

Objective. Our previous research showed that TCR+CD4-CD8-double-negative (DN) T cells protect renal epithelial cells from cisplatin-induced acute kidney injury (AKI). Therefore, this study is aimed at investigating the mechanism underlying the effect of DN T cells against Cis-induced AKI.

Methods. HK-2 cells cultured alone or with DN T cells were treated with or without Cis. After treatment, the cell viability and death were analyzed by a CCK-8 kit and flow cytometric assay with Annexin V/PI staining, respectively. The expressions of inflammatory factors in HK-2 and DN T cells were analyzed using qPCR. The expression levels of nephrotoxicity-associated biomarkers (KIM, calbindin, and TIMP-1), Bcl-2, and angiotensin AT2 receptor (AT2R) were determined by Western blot and qPCR.

Results. The administration of cisplatin significantly decreased the cell viability and AT2R expression, and increased cell death, inflammatory factors, and nephrotoxicity-associated biomarkers of HK-2 cells, while these effects were partly attenuated when cocultured with DN T cells. IL-10 expression was significantly increased in DN T cells after coculture, and cisplatin treatment aggravated this elevation. IL-10 supplementation exhibited a similar effect to coculture, whereas anti-IL-10 antibody reversed the effect of coculture on cisplatin-treated HK-2 cells. Finally, PD123319, an AT2R antagonist, also reversed the effect of IL-10 and coculture on the cell viability, death, and the expression of KIM, calbindin, TIMP-1, and Bcl-2 of cisplatin-treated HK-2 cells.

Conclusions. DN T cells protected HK-2 cells from cisplatin-induced injury through IL-10/AT2R axis, which may act as a potential target for the treatment of cisplatin-induced AKI.

1. Introduction

Cisplatin is now widely applied for the treatment of multiple cancers, but its major adverse reaction, acute kidney injury (AKI), limits its clinical use and has raised wide concerns [1, 2]. Approximately one-third of patient suffers from AKI after the treatment of cisplatin, and there is no strategy to effectively protect against such nephrotoxicity at present [3]. Hence, elucidating the pathogenesis of AKI induced by cisplatin is significant for developing agents that can attenuate this serious side effect given its widespread use as chemotherapy.

Over the past decades, the common mechanisms of cisplatin-induced AKI have been investigated extensively [4]. Multiple mechanisms are involved in cisplatin-induced nephrotoxicity, including oxidative stress, vascular injury, necrosis, and apoptosis, as well as inflammation. It is widely accepted that cisplatin-induced nephrotoxicity is attributed to platinum accumulation in renal tissue. The accumulation of cisplatin caused the excess production of reactive oxygen species (ROS) and tumor necrosis factor alpha (TNF-α) [5, 6], triggering oxidative stress [7], inflammation [8], and apoptotic pathways [9], which in turn to renal tissue damage and resulting in AKI. Recently, various studies emphasized the important role of inflammation in cisplatin-induced AKI. The activation of TNF-α and nuclear factor-kB (NF-kB) leads to proinflammatory cytokine production and cell infiltration thereby exacerbating kidney injury [10–12], while the inhibition of these molecules is associated with the improvement of cisplatin-induced AKI [5, 13]. Hence, uncovering the molecular mechanism underlying renal inflammation is an important research area that may lead to a potential therapy for patients with cisplatin-induced AKI.
Inflammatory responses in AKI involve several types of immune cells, including neutrophils, dendritic cells (DCs), macrophages, natural killer cells, and T lymphocytes [14]. DCs play a protective role in cisplatin-induced AKI [15]. Additionally, blocking neutrophil infiltration by the inhibition of the leukotriene B4-leukotriene B4 receptor axis had a protective effect against cisplatin-induced AKI [16]. As a type of T cell possessing tissue-protective, TCR+CD4-CD8-double-negative (DN) T cells are rarely present in the peripheral blood and lymphoid organs but the major T cell population in human and mouse kidneys [17]. Our previous study demonstrated that DN T cells protect kidney proximal tubular epithelial cells (PTECs) from cisplatin-induced AKI in vitro and in vivo [18]. However, there is very little information on the mechanism underlying the immunoregulatory roles of DN T cells to protect from cisplatin-induced AKI.

The aim of the present study was to perform a preliminary investigation into the effects of DN T cells on cisplatin-induced AKI and the underlying mechanism. Human Kidney 2 (HK-2) cell line was selected as model for receiving cisplatin stimulation in this study since it maintains biochemical properties and activity similar to in vivo proximal tubule cells [19].

2. Materials and Methods

2.1. Chemical Reagents and Antibodies. Cisplatin was purchased from Sigma-Aldrich (St. Louis, MO, USA). Anti-CD4 (RM4-5) APC/FITC/Pacific blue and anti-TCRβ (H57-597) FITC/BV421, CD45 (30-F11) APC-Cy7/BUV395, anti-CD8α (53 ± 6.7) PerCP-Cy5.5/APC-fire750, were purchased from BD Biosciences. Biotin-conjugated anti-CD16/32 (2.4G2) was purchased from BioLegend. Anti-CD4 (RM4-5) APC/FITC/Paciβ and anti-Bcl-2 antibodies were from Santa Cruz Biotechnology, Inc. (CA, USA). Anti-calbindin antibody was purchased from Cell Signaling Technology, Inc. (MA, USA).

2.2. Cell Culture. HK-2 cell line was purchased from Global Bioresource Center and cultured in HyClone™ DMEM/F12 supplemented with 5% FBS (Gibco, USA) at 37°C in a cell culture incubator. HK-2 cells were starved in the culture medium containing 0.5% FBS for 12 h and then administrated with cisplatin of indicated concentrations (20 or 40 μM) in the medium for 24 h. Then, the cells were subjected to protein extraction or carry out cell proliferation tests.

2.3. Coculture of HK-2 and DN T Cells. The coculture experiment was performed as we previously described [18]. In brief, HK-2 cells were plated in the upper chamber of 24-well plates at a density of 1.5 × 10⁴ cells per well and treated with or without cisplatin. DN T cells isolated from PMBCs using double negative T cell isolation kit (130-092-614, Miltenyi, Germany) were added to the lower chamber for cocultured with cisplatin-treated HK-2 cells at a ratio of 10:1 for 24 h at 37°C in a cell culture incubator.

2.4. CCK-8 Assay. Cell counting kit-8 (CCK-8) assay (Sangon Biotech, China) was applied to determine the cell viability of HK-2 cells. Cells were cultured in a 96-well plate at a density of 5,000 cells per well. 0.5 mg/mL CCK-8 (10 μL) solution was further added to each well, and cells were incubated for another 1 h at 37°C. The optical density was characterized at 450 nm by a microplate reader (Promega, USA).

2.5. Annexin V/PI Staining Assay. To detect cell death, Annexin V-FITC and Propidium Iodide (PI) Staining Solution purchased from BD Pharmingen were used in flow cyt fluorometric analyses. The Annexin V corresponding signal provides a very sensitive method for detecting cellular apoptosis, while PI is used to detect necrotic cells. After finishing treatment, HK-2 cells were resuspended in 100 μl per sample of the Annexin V/PI dilution and followed by incubation for 15 min in dark at room temperature. LSRII flow cytometer was used to analyze the indicated cells, and we analyzed the data by the FlowJo software.

2.6. Western Blot. The total cell lysates were collected by using precooled radioimmunoprecipitation assay (RIPA) lysis buffer (50 mM Tris–HCl, pH 7.8, 150 mM NaCl, and 1% Triton X-100, pH 7.8) with supplement of protease inhibitors for 30 min on ice, and then, the mixed liquor was centrifuged for 10 min at 14,000 × g. The lysates were subjected to extract protein by sodium dodecylsulfate–polyacrylamide gel electrophoresis (SDS-PAGE) and further transferred to polyvinylidene fluoride membranes (Millipore, USA). All the antibodies were diluted at 1 : 1,000 and then incubated overnight at 4°C. The secondary antibodies, conjugated to HRP, were diluted in TBST buffer (200 mM Tris base, pH 8.0, 1500 mM NaCl, and 0.1% Tween-20) at 1:5,000 and incubated for 1 h at room temperature. Enhanced chemiluminescence (ECL) mix was used to visualize the target proteins in a dark room.

2.7. Quantitative Reverse-Transcription Polymerase Chain Reaction (RT-qPCR). The total RNA of HK-2 or DN T cells was extracted by using TRIZOL reagents (Invitrogen, USA) according to the manual instructions. The cDNAs were synthesized by using a PrimeScript™ RT Reagent Kit (Takara Biotechnology, China), and the cDNAs of cells were further subjected to prepare the RT-qPCR samples with target primers and SYBR Green PCR Master Mix (Promega, USA). The samples were optimized for amplification with the following reaction conditions: denaturalization at 95°C for 10 min, 40 cycles at 95°C for 15 s, and 60°C for 1 min. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used for the expression control. Primers used for qPCR are shown in Table 1.

2.8. Statistical Analysis. Data were presented as mean ± SEM. Comparisons between groups were determined using one-way analysis of variance (ANOVA) using Prism 7 (GraphPad Software), and P < 0.05 indicated a significant difference.

3. Results

3.1. DN T Cells Attenuated Cisplatin-Induced Injury of HK-2 Cells. To verify the role of DN T cells in cisplatin-induced AKI, CCK-8 assay was conducted in HK-2 cells which were
pretreated with cisplatin. The results showed that the addition of DN T cells improved the cell viability of HK-2 cells with either 20 or 40 μM cisplatin, implying that DN T cells might protect HK-2 cells from cisplatin-induced cell death (Figure 1(a)).

To further confirm the protective role of DN T cells in cisplatin-induced cell death, the HK-2 cells were treated with DN T cells and 40 μM cisplatin and then subjected to flow cytometry by AV-FITC and PI staining. Both apoptosis and necrosis of HK-2 cells were enhanced by 40 μM cisplatin, but that was ameliorated by DN T cells, suggesting cisplatin promoted IL-10 secretion in DN T cells. Meanwhile, the IL-10 expression in HK-2 cells was also significantly increased after being treated alone by cisplatin, suggesting cisplatin promoted IL-10 secretion in HK-2 cells (Figure 2(a)). In summary, upon cisplatin administration, the IL-10 expression in HK-2 cells was increased, and IL-1β, IL-6, and TNF-α expression levels in HK-2 cells were decreased, implying that DN T cells might protect HK-2 cells from injury caused by cisplatin by affecting the development of inflammation.

3.2. Cisplatin Promoted IL-10 Expression in DN T Cells. Inflammation is considered to play a vital role in the pathophysiology of cisplatin-induced AKI, and treatment of AKI by regulating the expression of inflammatory factors has been proposed. Therefore, it is necessary to explore whether the addition of DN T cells affects the expression of inflammatory factors. Thus, the expression levels of IL-1β, IL-6, TNF-α, and IL-10 in HK-2 cells were detected after DN T cell and cisplatin treatment. The expression levels of these inflammatory factors in HK-2 cells were significantly increased after cisplatin treatment compared with the control cells, but their expression levels were decreased upon the coculture with DN T cells, indicating that DN T cells inhibited the inflammatory process of HK-2 cells induced by cisplatin (Figure 2(a)). However, there is no change expression of IL-10 in cisplatin-treated HK-2 cells after the coculture with DN T cells, suggesting that DN T cells did not affect IL-10 expression in HK-2 cells (Figure 2(a)).

Moreover, IL-17A, INF-γ, TNF-α, and IL-10 within DN T cells were also determined in our study. Upon different treatments, the expressions of IL-17A, INF-γ, and TNF-α in DN T cells have not changed. Surprisingly, the IL-10 expression in DN T cells was distinctly increased when DN T cells were cocultured with HK-2 cells, while this change was further aggravated by the addition of cisplatin. Consistent with the previous results, coculture with DN T cells could attenuate the cell death induced by cisplatin (Figures 1(b) and 1(c)). In summary, these results revealed that DN T cells protected HK-2 cells from injury caused by cisplatin via reducing cell death and increasing cell viability.

3.3. Enhanced IL-10 Expression in DN T Cells Reduced HK-2 Cell Injury Induced by Cisplatin. We further investigated whether IL-10 is involved in the protection of HK-2 cells against cisplatin-induced AKI. Consistent with the previous results, coculture with DN T cells could attenuate the cell death induced by cisplatin in HK-2 cells (Figures 3(a)–3(c)). Notably, the addition of IL-10 exerted a similar function to the coculture in cisplatin-treated HK-2 cells, whereas the addition of anti-IL-10 antibody almost neutralized the effects of the coculture on cisplatin-treated HK-2 cells (Figures 3(a)–3(c)).

Furthermore, the expression levels of nephrotoxicity-related markers (KIM, calbindin, and TIMP-1) and the anti-apoptosis protein (Bcl-2) were determined by Western blot and qPCR. As shown in Figure 3(d), upon the stimulation of cisplatin, the expression of KIM, calbindin, and TIMP-1 was increased while Bcl-2 expression was reduced in HK-2 cells, confirming the nephrotoxicity of cisplatin for HK-2 cells. The deleterious role of cisplatin was blocked by both

| Table 1: Sequences of PCR primers used in this study. |
|---------------------------------|---------------------------------|
| GAPDH  | Forward (5'-3') |
|        | Reverse (5'-3') |
| IL-1β  | Forward (5'-3') |
|        | Reverse (5'-3') |
| IL-6   | Forward (5'-3') |
|        | Reverse (5'-3') |
| TNF-α  | Forward (5'-3') |
|        | Reverse (5'-3') |
| IL-10  | Forward (5'-3') |
|        | Reverse (5'-3') |
| IFN-γ  | Forward (5'-3') |
|        | Reverse (5'-3') |
| IL-17A | Forward (5'-3') |
|        | Reverse (5'-3') |
| AT2R   | Forward (5'-3') |
|        | Reverse (5'-3') |
|        | TGTGGGCATCAATGGATTTGG |
|        | ACACCATGTAATCCGGGTCAAT |
|        | TGGTGCGAGTCCTATGTCT |
|        | GGGAACATCACACACTAGCA |
|        | CAGTTCAGGTTCCTTCTCCC |
|        | CATCTTCTCAAAACTCGAGTGACAA |
|        | TGGGAGTAGATAAGGTACAGCCC |
|        | GGCCAAGCTGTCGAGTAGATCC |
|        | TTTGACATGCCCTTGATGTCTGG |
|        | AGCCATCGATGTTTTGGG |
|        | GTTCAATTATTCGCTACATCTGAA |
|        | CCTCAAGTTTACCTT |
|        | CACCAGCATTCCTCCAC |
|        | TAAGCTGATTTATGAACTGC |
|        | ATATGAAACTCGAGCACTC |
HK-2+DN T

1.5
1.0
0.5
0.0
24 48 72 96
Time (h)

Cell viability

HK-2+DN T+Cis (20 μM)
HK-2+Cis (20 μM)

⁎
⁎⁎
⁎ampus
⁎ampus

HK-2+DN T+Cis (40 μM)

⁎
⁎ampus
⁎ampus

(a)

HK-2

10^4
10^3
10^2
10^1
10^1 10^2 10^3 10^4
Q1-1
Q1-2
Q1-3
Q1-4
0.31%
3.34%
3.19%
2.04%

HK-2+Cis

10^4
10^3
10^2
10^1
10^1 10^2 10^3 10^4
Q1-1
Q1-2
Q1-3
Q1-4
0.18%
7.82%
8.96%
2.48%

HK-2+DN T

10^4
10^3
10^2
10^1
10^1 10^2 10^3 10^4
Q1-1
Q1-2
Q1-3
Q1-4
0.48%
3.57%
0.67%
2.28%

HK-2+DN T+Cis

10^4
10^3
10^2
10^1
10^1 10^2 10^3 10^4
Q1-1
Q1-2
Q1-3
Q1-4
0.42%
4.79%
0.36%
1.43%

(b)

Figure 1: Continued.
the coculture with DN T cells and IL-10 administration. In line with the result of CCK-8 and Annexin V/PI staining assays, the effect of the coculture on the nephrotoxicity-related markers and antiapoptosis protein in HK-2 cells was restored by the addition of anti-IL-10 antibody (Figure 3(d)). These data collectively revealed that the protective function of DN T cells on HK-2 cells under cisplatin is mediated by IL-10.

3.4. IL-10-Induced AT2R Expression Protects HK-2 Cells against Cisplatin-Induced AKI. To further uncover the molecular mechanism underlying the protective effect of DN T cells on cisplatin-treated HK-2 cells, the expression of angiotensin AT2 receptor (AT2R, a renoprotective protein that could be regulated by IL-10) at both mRNA and protein levels was determined using Western blot and qPCR. The results showed that the expression of AT2R in HK-2 cells treated with cisplatin and DN T cells was significantly higher than that in the cisplatin-treated control group. These findings suggest that the protective effect of DN T cells on HK-2 cells under cisplatin treatment is mediated by IL-10-induced AT2R expression.
Figure 3: Continued.
cells was decreased upon cisplatin treatment (Figures 4(a) and 4(b)). The addition of IL-10 restored the decreased expression of AT2R in cisplatin-treated HK-2 cells (Figures 4(a) and 4(b)). In the meantime, cocultured with DN T cells also increased the expression of AT2R in cisplatin-treated HK-2 cells (Figures 4(a) and 4(b)), suggesting that DN T cells secreted IL-10 resulted in the upregulation of AT2R in cisplatin-treated HK-2 cells. Subsequently, PD123319, a potent antagonist of AT2R, was used to investigate whether AT2R is involved in the process of DN T cells protecting against cisplatin-induced injury in HK-2 cells. CCK-8 assay and flow cytometry showed that the protective effect of AT2R in cisplatin-treated HK-2 cells (Figures 4(a) and 4(b)), suggesting that DN T cells secreted IL-10 resulted in the upregulation of AT2R in cisplatin-treated HK-2 cells. Subsequently, PD123319, a potent antagonist of AT2R, was used to investigate whether AT2R is involved in the process of DN T cells protecting against cisplatin-induced injury in HK-2 cells.

Then, AT2R could influence the expression of nephrotoxicity-associated biomarkers, and antiapoptosis protein was addressed by Western blot assay. Our findings demonstrated that PD123319 effectively increased the expression of KIM, calbindin, and TIMP-1 and reduced the Bcl-2 expression in the cisplatin-treated HK-2 cells added with either DN T cells or IL-10 (Figure 4(f)), suggesting that AT2R suppression could block the effect of DN T cells and IL-10 on these protein expression in cisplatin-treated HK-2 cells. In general, these data indicated that DN T cells attenuated cisplatin-induced AKI by downregulating inflammatory factors of HK-2 cells and possibly upregulating anti-inflammatory factors of HK-2 cells through IL-10/AT2R pathway, which provided evidence for the treatment of cisplatin-induced AKI by inhibiting inflammation.

4. Discussion

Emerging evidence from patients and animal models has suggested that inflammation plays a major role in the pathological processes of cisplatin-induced AKI [20]. The complex inflammatory process is coregulated by various types of immune cells and chemokines. Studies have shown that in cisplatin-induced AKI, activated CD4+T cells in filtrate injured kidneys by secreting TNF-α [21]. In addition to the pathophysiologic role in AKI, certain immune cells have been proven to inhibit the progression of AKI [14]. CD4+CD25+Foxp3+ regulatory T (Treg) cells exerted the therapeutic potential by facilitating the repair process and reduced proinflammatory cytokine production by other T cell subsets in AKI [22]. Inducing tolerogenic DCs by adenosine 2A receptor agonist could protect the kidney from ischemia-reperfusion injury by suppressing natural killer T cells [23]. All these reports suggested the therapeutic potential of targeting immune cells in AKI. Our recent work has demonstrated that DN T cells, a rare and heterogeneous T

![Graphs and images](image-url)
Figure 4: Continued.
(d) Necrotic cells (%)

(e) Apoptotic cells (%)

Figure 4: Continued.
DN T cells could decrease IL-1 in the early phase of AKI [17]. These data suggested that only IL-10 was dramatically increased in DN T cells has been analyzed in the meantime. Our data showed that DN T cells with cisplatin-treated HK-2 cells exhibited a lower level of IL-10, INF-γ, and TNF-α in DN T cells by secreting the high levels of IL-10. IL-10 has been proven to protect against renal injury induced by different factors, such as diabetes [26], ischemia-reperfusion [27], and cisplatin [28]. We, therefore, sought to determine whether IL-10 is involved in the protective effect of DN T cells in cisplatin-treated HK-2 cells. As expected, neutralizing IL-10 antibody supplementation abrogated the protective effect of DN T cells-mediated improvement in cisplatin-induced AKI of DN T cells in attenuating cisplatin-induced AKI. Given the close relationship between AT2R and IL-10, we wonder whether the renoprotective function of IL-10 is associated with AT2R. In our study, it was found that AT2R expression in cisplatin-treated HK-2 cells, suggesting that the protective function of IL-10 secreting by DN T cells...
on HK-2 cells may be mediated by AT2R. Hence, our study used PD123319, an AT2R agonist, to block the function of AT2R and determine whether AT2R is involved in the effect of IL-10 on cisplatin-treated HK-2 cells. As expected, blocking AT2R activation effectively reversed the effect of both DN T cells and IL-10 on the cisplatin-injury of HK-2 cells, which confirmed that AT2R is an important mediator of the protective role of DN T cells in cisplatin-treated HK-2 cells. Since the kidney is only second to the heart in mitochondrial damage and oxygen consumption [32], mitochondrial damage induced by oxidative stress is another culprit of cisplatin-induced AKI. Except for anti-inflammatory effects, AT2R has been reported to reduce oxidative stress in multiple diseases [33, 34]. Therefore, DN T cells attenuate cisplatin-induced AKI by reducing inflammation and oxidative stress via IL-10/AT2R axis. However, how IL-10 affects the activity of AT2R in cisplatin-treated HK-2 cells remains unknown. Future work uncovering the reason IL-10 derived from DN T cells could further increase AT2R expression to protect HK-2 cells from cisplatin-induced injury will provide new insights into the mechanism of cisplatin-induced AKI.

In conclusion, our findings suggested that DN T cells protected HK-2 cells from cisplatin-induced AKI through IL-10/AT2R axis, which provides important implications for the prevention of cisplatin-induced nephrotoxicity and for the treatment of other renal injury diseases.

**Data Availability**

This manuscript has no associated data.

**Conflicts of Interest**

The authors declared that no competing interest exists.

**References**

[1] H. Mehanna, M. Robinson, A. Hartley et al., "Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCA-LaTE HPV): an open-label randomised controlled phase 3 trial," *Lancet*, vol. 393, no. 10166, pp. 51–60, 2019.

[2] N. A. dos Santos, M. A. Carvalho Rodrigues, N. M. Martins, and A. C. dos Santos, “Cisplatin-induced nephrotoxicity and targets of nephroprotection: an update,” *Archives of Toxicology*, vol. 86, no. 8, pp. 1233–1250, 2012.

[3] J. D. Stewart and H. M. Bolt, “Cisplatin-induced nephrotoxicity,” *Archives of Toxicology*, vol. 86, no. 8, pp. 1155-1156, 2012.

[4] K. R. McSweeney, L. K. Gadanc, T. Qaradakhi, B. A. Ali, A. Zulli, and V. Apostolopoulos, “Mechanisms of cisplatin-induced acute kidney injury: pathological mechanisms, pharmacological interventions, and genetic mitigations,” *Cancers*, vol. 13, no. 7, p. 1572, 2021.

[5] G. Ramesh and W. B. Reeves, “TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity,” *The Journal of Clinical Investigation*, vol. 110, no. 6, pp. 835–842, 2002.

[6] B. Zhang, G. Ramesh, C. C. Norbury, and W. B. Reeves, “Cisplatin-induced nephrotoxicity is mediated by tumor necrosis factor-alpha produced by renal parenchymal cells,” *Kidney International*, vol. 72, no. 1, pp. 37–44, 2007.

[7] H. Soni, D. Kaminski, R. Ganganaraju, and A. Adebiyi, “Cisplatin-induced oxidative stress stimulates renal Fas ligand shedding,” *Renal Failure*, vol. 40, no. 1, pp. 314–322, 2018.

[8] P. Liu, X. Li, W. Lv, and Z. Xu, “Inhibition of CXCL1–CXCR2 axis ameliorates cisplatin-induced acute kidney injury by mediating inflammatory response,” *Biomedicine & Pharmacotherapy*, vol. 122, p. 109693, 2020.

[9] J. Ni, X. Hou, X. Wang et al., “3-deazaneplanocin a protects against cisplatin-induced renal tubular cell apoptosis and acute kidney injury by restoration of E-cadherin expression,” *Cell Death & Disease*, vol. 10, no. 5, p. 355, 2019.

[10] A. M. El-Garhy, O. M. Abd El-Raouf, B. M. El-Sayeh, H. M. Fawzy, and D. M. Abdallah, “Ellagic acid anti-inflammatory and antiapoptotic potential mediate renoprotection in cisplatin nephrotoxic rats,” *Journal of Biochemical and Molecular Toxicology*, vol. 28, no. 10, pp. 472–479, 2014.

[11] M. Ueki, M. Ueno, J. Morishita, and N. Maekawa, “Curcumin ameliorates cisplatin-induced nephrotoxicity by inhibiting renal inflammation in mice,” *Journal of Bioscience and Bioengineering*, vol. 115, no. 5, pp. 547–551, 2013.

[12] A. B. Sanz, M. D. Sanchez-Niño, A. M. Ramos et al., “NF-κB in renal inflammation,” *Journal of the American Society of Nephrology*, vol. 21, no. 8, pp. 1254–1262, 2010.

[13] H. D. Francescato, R. S. Costa, C. Scavone, and T. M. Coimbra, “Parthenolide reduces cisplatin-induced renal damage,” *Toxicology*, vol. 230, no. 1, pp. 64–75, 2007.

[14] S. A. Lee, S. Noel, M. Sadasivam, A. R. A. Hamad, and H. Rabb, "Role of immune cells in acute kidney injury and repair," *Nephron*, vol. 137, no. 4, pp. 282–286, 2017.

[15] R. K. Tadagavadi and W. B. Reeves, "Renal dendritic cells ameliorate nephotoxic acute kidney injury," *Journal of the American Society of Nephrology*, vol. 21, no. 1, pp. 53–63, 2010.

[16] B. Deng, Y. Lin, S. Ma et al., "The leukotriene B4–leukotriene B4 receptor axis promotes cisplatin-induced acute kidney injury by modulating neutrophil recruitment," *Kidney International*, vol. 92, no. 1, pp. 89–100, 2017.

[17] M. N. Martina, S. Noel, A. Saxena et al., "Double-negative αβ T cells are early responders to AKI and are found in human kidney," *Journal of the American Society of Nephrology*, vol. 27, no. 4, pp. 1113–1123, 2016.

[18] J. Gong, S. Noel, J. Hsu et al., "TCR+(+CD4(-)(CD8(-)) (double negative) T cells protect from cisplatin-induced renal epithelial cell apoptosis and acute kidney injury," *American Journal of Physiology. Renal Physiology*, vol. 318, no. 6, pp. F1500–F1512, 2020.

[19] P. Gunnness, K. Aleksa, K. Kosuge, S. Ito, and G. Koren, "Comparison of the novel HK-2 human renal proximal tubular cell line with the standard LLC-PK1 cell line in studying drug-induced nephrotoxicity," *Canadian Journal of Physiology and Pharmacology*, vol. 88, no. 4, pp. 448–455, 2010.

[20] A. Ozkok and C. L. Edelstein, "Pathophysioloogy of cisplatin-induced acute kidney injury," *BioMed Research International*, vol. 2014, Article ID 967826, 17 pages, 2014.

[21] M. Liu, C. C. Chien, M. Burns-Taney et al., "A pathophysiological role for T lymphocytes in murine acute cisplatin nephrotoxicity," *Journal of the American Society of Nephrology*, vol. 17, no. 3, pp. 765–774, 2006.

[22] M. T. Gandolfo, H. R. Jang, S. M. Bagnasco et al., "Foxp3+ regulatory T cells participate in repair of ischemic acute kidney injury," *Kidney International*, vol. 76, no. 7, pp. 717–729, 2009.
[23] M. D. Okusa and L. Li, “Dendritic cells in acute kidney injury: cues from the microenvironment,” Transactions of the American Clinical and Climatological Association, vol. 123, pp. 54–62, 2012.

[24] A. Paolicchi, M. Sotiropoulo, P. Perego et al., “Gamma-glutamyl transpeptidase catalyses the extracellular detoxification of cisplatin in a human cell line derived from the proximal convoluted tubule of the kidney,” European Journal of Cancer, vol. 39, no. 7, pp. 996–1003, 2003.

[25] J. C. Crispín, M. Oukka, G. Bayliss et al., “Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys,” Journal of Immunology, vol. 181, no. 12, pp. 8761–8766, 2008.

[26] D. H. Kim, S. Y. Chun, E. H. Lee et al., “IL-10 deficiency aggravates renal inflammation, fibrosis and functional failure in high-fat dieted obese mice,” Journal of Tissue Engineering and Regenerative Medicine, vol. 18, no. 3, pp. 399–410, 2021.

[27] K. Sakai, Y. Nozaki, Y. Murao et al., “Protective effect and mechanism of IL-10 on renal ischemia-reperfusion injury,” Laboratory Investigation, vol. 99, no. 5, pp. 671–683, 2019.

[28] W. W. Wang, Y. Wang, K. Li et al., “IL-10 from dendritic cells but not from T regulatory cells protects against cisplatin-induced nephrotoxicity,” PLoS One, vol. 15, no. 9, article e0238816, 2020.

[29] E. N. Haugen, A. J. Croatt, and K. A. Nath, “Angiotensin II induces renal oxidant stress in vivo and heme oxygenase-1 in vivo and in vitro,” Kidney International, vol. 58, no. 1, pp. 144–152, 2000.

[30] S. Patel, I. Dhande, E. A. Gray, Q. Ali, and T. Hussain, “Prevention of lipopolysaccharide-induced CD11b+ immune cell infiltration in the kidney: role of AT2 receptors,” Bioscience Reports, vol. 39, no. 5, 2019.

[31] R. Ali, S. Patel, and T. Hussain, “Angiotensin type 2 receptor activation limits kidney injury during the early phase and induces Treg cells during the late phase of renal ischemia,” American Journal of Physiology. Renal Physiology, vol. 320, no. 5, pp. F814–f825, 2021.

[32] P. Duann and P. H. Lin, “Mitochondria damage and kidney disease,” Advances in Experimental Medicine and Biology, vol. 982, pp. 529–551, 2017.

[33] S. Y. Chang, Y. W. Chen, I. Chenier, M. Tran Sle, and S. L. Zhang, “Angiotensin II type II receptor deficiency accelerates the development of nephropathy in type I diabetes via oxidative stress and ACE2,” Experimental Diabetes Research, vol. 2011, Article ID 521076, 12 pages, 2011.

[34] J. Lu, L. Wu, T. Jiang et al., “Angiotensin AT2 receptor stimulation inhibits activation of NADPH oxidase and ameliorates oxidative stress in rotenone model of Parkinson’s disease in CATH.a cells,” Neurotoxicology and Teratology, vol. 47, pp. 16–24, 2015.